September 22, 2023Amendment and Restatement of Common Stock Purchase Warrants • March 29th, 2024 • Galectin Therapeutics Inc • Pharmaceutical preparations • Florida
Contract Type FiledMarch 29th, 2024 Company Industry JurisdictionThis letter agreement (this “Letter Agreement”) confirms the agreement between Galectin Therapeutics, Inc. (the “Company”) and 10X Fund L.P. and 10X Capital Management LLC (collectively referred to as “10X”) regarding certain amendments with respect to an aggregate of 5,732,253 Common Stock Purchase Warrants (the “Series B Warrants”) held by 10X, which are listed on Schedule A.